Zydus Lifesciences secured FDA review: Neutral rating for Zydus Lifesciences stock

Zydus Lifesciences (INE010B01027) secured US regulatory review for FYB206, a proposed Keytruda biosimilar, on October 13, 2026. The Economic Times reported that the US Food and Drug Administration accepted the application, while Zydus holds exclusive commercialization rights for the United States and Canada.

Three milestones shape the story

On September 28, 2026, Zydus shares reached INR 1,228.60 on the National Stock Exchange after a US FDA inspection at the company's New Jersey office concluded with nil observations, according to Upstox.

On October 6, 2026, Zydus and MSN Laboratories launched the first generic version of Adempas, or riociguat, in the United States across five strengths, as reported by Ground News. On October 13, 2026, the FDA accepted the FYB206 biologics license application for review, with a decision expected in the third quarter of 2027, according to The Economic Times.

What does the latest margin trend show?

The regulatory pipeline arrives alongside a mixed operating picture. In the first quarter of fiscal 2027, revenue from operations rose 20.74 percent year over year to INR 80.17 billion, while consolidated net profit fell 35.93 percent to INR 9.40 billion, according to Upstox. EBITDA declined 7.60 percent to INR 19.29 billion, and the EBITDA margin contracted to 24.10 percent from 31.80 percent.

That contrast explains why FYB206 matters strategically but does not settle the earnings debate. The latest quarter paired strong top-line growth with lower profitability, leaving future product launches and regulatory execution important for the valuation narrative.

When is the next regulatory milestone?

The next substantiated milestone is the US FDA decision on FYB206, expected in the third quarter of 2027. The Economic Times said the application was developed without a comparative Phase III efficacy trial and remains subject to regulatory approval and intellectual-property considerations.

Stock context and valuation

Zydus Lifesciences had a market capitalization of INR 1.1 trillion on October 16, 2026. Its 52-week range was INR 835.50 to INR 1,232.10, placing the latest Indian quotation near the upper end of that range. The company is listed on the National Stock Exchange under ZYDUSLIFE and on the Bombay Stock Exchange under code 532321.

Zydus Lifesciences is a pharmaceutical group spanning generic medicines, vaccines, biosimilars, specialty therapies and consumer products. The company says its research network includes 1,500 researchers across 19 sites, while its wider group employs more than 30,000 people.

Regulatory progress meets earnings pressure

FYB206 gives Zydus a visible oncology catalyst, but the first-quarter margin contraction keeps execution central to the stock discussion. The next regulatory update is scheduled for the third quarter of 2027.

Market context: Market report BSE Sensex.

More news and analyses on Zydus Lifesciences stock